According to a release issued by Wockhardt to the BSE on Monday, Zonisamide is the generic version of Dainippon's Zonegran capsules.
As per IMS data, the current market of Zonisamide in the US is $174 million, the release added.
"Wockhardt will be the first company to launch generic Zonisamide in the US. We have received the ANDA approval in less than nine months from filing date," Habil Khorakiwala, chairman of Wockhardt, said.
Zonisamide is the first compound of its class to be developed as an anti-epileptic agent.
"It has the broad spectrum of anti-epileptic activity, and is particularly beneficial in refractory partial seizures and to a more variable extent in generalised and compound/combination seizures," Khorakiwala added.